# Daily Temporal Associations Between Use of Psychoactive Substances and Fatigue, Pain, Stress, and Depressive Symptoms in People With Multiple Sclerosis. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/ms-patients-cannabis-pain-ecological-momentary-assessment-study/ > **Published:** 2026-04-27T23:17:10-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:00:17-04:00 > **Clinical Summary:** New ecological study shows MS patients increase cannabis use and decrease alcohol consumption during pain episodes, suggesting therapeutic self-medication patte --- CED Clinical Relevance  #64Notable Clinical Interest Evidence Brief | CED ClinicEcological momentary assessment reveals that daily stress increases [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and reduces alcohol use among people with [multiple sclerosis](https://cedclinic.com/respiratory-function-exercise-therapy-ms/). [Multiple Sclerosis](https://cedclinic.com/respiratory-function-exercise-therapy-ms/)CannabisPainStressEma Ecological momentary assessment reveals that daily stress increases [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and reduces alcohol use among people with multiple sclerosis. What This Study Teaches Us This study demonstrates that people with MS modify their [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) in response to fluctuating symptoms on a day-to-day basis. The ecological momentary assessment design captures real-time symptom-substance use relationships that retrospective surveys miss, revealing distinct patterns where stress drives cannabis use while pain reduces alcohol consumption. Why This Matters These findings suggest that [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) in MS represents symptom-directed self-medication rather than recreational behavior. Understanding these temporal patterns helps clinicians recognize when patients may be using substances to manage breakthrough symptoms and guides more nuanced conversations about therapeutic alternatives. Study Snapshot Study Type Prospective Longitudinal Cohort Study with Ecological Momentary Assessment Population 258 ambulatory adults with multiple sclerosis Intervention Four daily smartphone assessments over 14 days at baseline, 1-year, and 2-year follow-ups Comparator Within-person temporal comparisons Primary Outcome Daily associations between symptom severity and psychoactive substance use patterns Key Finding Momentary stress increases predicted cannabis use; higher average pain was associated with reduced alcohol use and increased other substance use Journal Archives of Physical Medicine and Rehabilitation Year 2024 Clinical Bottom Line People with MS appear to use cannabis as an acute [stress response](https://cedclinic.com/salivary-cortisol-measurement-cannabis-insights/) tool and avoid alcohol during periods of higher pain. This represents rational self-medication behavior that clinicians should acknowledge when discussing symptom management strategies. What This Paper Does Not Show The study cannot establish whether substance use actually improves symptoms or represents effective self-medication. The abstract does not provide specific effect sizes, confidence intervals, or information about cannabis products used, limiting clinical application. Where This Paper Deserves Skepticism Self-reported substance use may be subject to social desirability bias, and smartphone-based assessments may miss usage patterns in patients with cognitive symptoms. The temporal associations shown do not prove causation, and confounding by unmeasured factors remains possible. Dr. Caplan's Take I see this pattern clinically – patients with MS often describe using cannabis when stress peaks and avoiding alcohol during flares. This study validates what many patients already know about their bodies, though it doesn’t tell us whether their self-medication strategies are actually helping their symptoms. What a Careful Reader Should Take Away This research documents that substance use patterns in MS are symptom-responsive rather than purely recreational. Clinicians should view these behaviors as potential self-medication attempts and use them as starting points for discussing evidence-based symptom management approaches. Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Daily%20Temporal%20Associations%20Between%20Use%20of%20Psychoactive%20Substances%20and%20Fatigue%2C%20Pain%2C%20Stress%2C%20and%20De...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2Fms-patients-cannabis-pain-ecological-momentary-assessment-study%2F)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fms-patients-cannabis-pain-ecological-momentary-assessment-study%2F)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Daily%20Temporal%20Associations%20Between%20Use%20of%20Psychoactive%20Substances%20and%20Fatigue%2C%20Pain%2C%20Stress%2C%20and%20De...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2Fms-patients-cannabis-pain-ecological-momentary-assessment-study%2F)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Table of Contents - [FAQ](#FAQ)[How does daily stress affect substance use patterns in people with multiple sclerosis?](#How_does_daily_stress_affect_substance_use_patterns_in_people_with_multiple_sclerosis) - [Should clinicians be concerned about pain levels influencing substance use in MS patients?](#Should_clinicians_be_concerned_about_pain_levels_influencing_substance_use_in_MS_patients) - [How reliable is ecological momentary assessment for tracking substance use in MS patients?](#How_reliable_is_ecological_momentary_assessment_for_tracking_substance_use_in_MS_patients) - [What should clinicians know about cannabis use patterns in their MS patients?](#What_should_clinicians_know_about_cannabis_use_patterns_in_their_MS_patients) - [How can this research inform treatment planning for MS patients using psychoactive substances?](#How_can_this_research_inform_treatment_planning_for_MS_patients_using_psychoactive_substances) - [Related](#Related) ## FAQ #### How does daily stress affect substance use patterns in people with multiple sclerosis? This study found that momentary increases in stress predict reduced alcohol use but increased cannabis use among people with MS. The findings suggest that individuals with MS may turn to cannabis rather than alcohol as a coping mechanism during stressful periods. #### Should clinicians be concerned about pain levels influencing substance use in MS patients? Yes, the research shows that higher average pain levels are associated with reduced alcohol consumption and increased use of other substances. Clinicians should monitor [pain management](https://cedclinic.com/cbd-cbg-topicals-for-eczema/) strategies and discuss substance use patterns as part of comprehensive MS care. #### How reliable is ecological momentary assessment for tracking substance use in MS patients? EMA provides highly reliable real-time data by capturing substance use and symptoms 4 times daily over extended periods. This method reduces recall bias and provides more accurate temporal associations between symptoms and substance use compared to traditional retrospective reporting. #### What should clinicians know about cannabis use patterns in their MS patients? The study reveals that cannabis use increases in response to daily stress among people with MS, suggesting it may serve as a stress-management tool. Clinicians should have open discussions about cannabis use patterns and consider this when developing comprehensive symptom management plans. #### How can this research inform treatment planning for MS patients using psychoactive substances? Understanding the temporal relationships between symptoms and substance use can help clinicians identify when patients are most likely to self-medicate. This knowledge enables more targeted interventions and alternative coping strategies during high-stress or high-pain periods. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).